A global systematic review has revealed that the shingles vaccine may reduce the risk of cardiovascular events in adults. The analysis found that receiving the vaccine was associated with an 18% lower risk of heart attack or stroke, with slightly lower but still significant benefits for adults over 50.
The study, the first of its kind worldwide, analyzed data from 19 studies, including randomized controlled trials and observational research. Researchers suggest the protective effect could be linked to reducing inflammation caused by shingles, which is known to contribute to heart and circulatory problems.
Experts have welcomed the findings but emphasized the need for further research, particularly to confirm the results in younger adults and to establish a causal relationship. Meanwhile, health authorities are expanding eligibility for the shingles vaccine, recognizing its potential benefits beyond preventing viral infection.
